NanoString | GenomeWeb

NanoString

Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.

The firm expects full-year revenue growth of up to 39 percent, but fell short of prior guidance for the year.

It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.

The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests. 

Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.

The Seattle-based firm is working with Oregon Health & Science University researcher Lisa Coussens on a tool for studying the innate immune system in oncology.

The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.

Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.

The molecular analysis firm saw instrument sales rise 62 percent, and announced plans for a new digital spatial profiling instrument.

The researchers will use genomics to address challenges facing Canada's forestry, healthcare, agricultural, and aquacultural industries.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.